Navigation Links
Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market
Date:1/28/2008

BASKING RIDGE, N.J., Jan. 28 /PRNewswire-FirstCall/ -- Millennium Biotechnologies, Inc., a wholly owned subsidiary of Millennium Biotechnologies Group, Inc. (OTC Bulletin Board: MBTG), reports continued success of their international distribution partnership for the Resurgex(R) line of products in Greece. Since first delivering product to Nutrimedica in April 2006 overall sales in the Greek Market have increased approximately 40% from $30,000 in 2006 to $50,000 in 2007. A successful entry of a U.S. product into the Greek market depends on proper selection of a qualified distributor in Greece, which is knowledgeable of the local market and regulations. The distributor must be capable of developing a proper relationship with the distribution chain of medical institutions, practitioners and proper retail outlets in the medical marketplace. For the past 22 months Millennium has working with Nutrimedica, a well known distributor of nutritional products, in Athens. It has already imported and distributed Resurgex(R) products to hospitals, pharmacies, and direct to patients. Nutrimedica reports that the introduction of Resurgex products has been well received and sales have been steadily increasing. The steady growth has been encouraging due to the fact that no marketing dollars have been allocated to build brand awareness in the marketplace.

About Millennium:

Millennium's three proprietary, marketed products, which form the Company's Resurgex(R) Continuum of Care, include Resurgex Select(R), Resurgex(R), and Resurgex Plus(R). Resurgex Select(R) is a whole foods-based, calorically dense, high-protein nutritional formula developed for cancer patients undergoing chemotherapy or radiation treatments. Resurgex(R) and Resurgex Plus(R) are specialized, anabolic nutritional supplements rich in antioxidants that provide nutritional support post-treatment. Millennium is also recently developed a Surgex(R) sports nutrition formula, clinically proven to address the nutritional concerns of both professional and amateur elite athletes. These athletes often experience similar symptoms post-workout to those battling immunocompromised conditions, such as fatigue, loss of lean muscle, oxidative stress, and reduced immune function.

Statements in this news release regarding future financial and operating results, future growth in R&D programs, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward- looking statements including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of the Company's intellectual property, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic reports, including Forms 10-KSB, 10-QSB, 8-K, and other forms filed with the Securities and Exchange Commission ("SEC").


'/>"/>
SOURCE Millennium Biotechnologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results
2. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection
3. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order
4. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets
5. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market
6. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales
7. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results
8. Life Sciences Leader Joins Millennium Board of Directors
9. Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference to Webcast Millennium Presentation
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... , ... May 24, 2017 , ... ... are increasingly being developed with Wi-Fi connectivity to reduce the amount of wiring ... to room. In addition, compact mobile devices including infusion pumps, heart and hypertension ...
(Date:5/23/2017)... ... May 23, 2017 , ... ... cells for research and the development of cardiac regeneration therapies. The development ... numbers of cardiomyocytes (hPSC-CMs). Due to varying differentiation efficiencies, further enrichment of ...
(Date:5/23/2017)... MENLO PARK, CA (PRWEB) , ... May 23, 2017 , ... ... announced the publication of “Label-free isolation of prostate circulating tumor cells using Vortex ... publication is the result of a collaboration with Dr. Dino Di Carlo and Dr. ...
(Date:5/23/2017)... ... May 23, 2017 , ... Cambridge Semantics , the leading provider ... Bio-IT World Conference and Expo in Boston May 23-25 with a featured ... The Anzo Smart Data Lake is also a finalist for the Best of Show ...
Breaking Biology Technology:
(Date:4/17/2017)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... 2016 Annual Report on Form 10-K on Thursday April 13, 2017 ... ... Investor Relations section of the Company,s website at http://www.nxt-id.com  under ... http://www.sec.gov . 2016 Year Highlights: ...
(Date:4/11/2017)... , April 11, 2017 No ... but researchers at the New York University Tandon ... of Engineering have found that partial similarities between ... systems used in mobile phones and other electronic ... The vulnerability lies in the fact ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):